Cargando…

Assessing and managing medication overuse headache in Australian clinical practice

More than 3 million Australians are estimated to have migraine disorders, and over a quarter of a million Australians are estimated to have medication overuse headache (MOH). The personal, societal and economic burden of MOH is high. MOH impacts an individual’s ability to work or study, care for fam...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijeratne, Tissa, Jenkins, Bronwyn, Stark, Richard J, Sun-Edelstein, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255228/
https://www.ncbi.nlm.nih.gov/pubmed/37304309
http://dx.doi.org/10.1136/bmjno-2023-000418
_version_ 1785056820797112320
author Wijeratne, Tissa
Jenkins, Bronwyn
Stark, Richard J
Sun-Edelstein, Christina
author_facet Wijeratne, Tissa
Jenkins, Bronwyn
Stark, Richard J
Sun-Edelstein, Christina
author_sort Wijeratne, Tissa
collection PubMed
description More than 3 million Australians are estimated to have migraine disorders, and over a quarter of a million Australians are estimated to have medication overuse headache (MOH). The personal, societal and economic burden of MOH is high. MOH impacts an individual’s ability to work or study, care for family or themselves, culminating in poor quality of life. Accurate and timely diagnosis and treatment of MOH are imperative. Withdrawal failures and relapse rates are high in MOH. Treatment of MOH is aimed at ceasing medication overuse and reducing monthly migraine days with the aim of achieving a pattern of well-controlled episodic migraine. Current treatment approaches in routine practice include withdrawal with preventive treatment, withdrawal with optional preventive treatment in the subsequent weeks and preventive treatment without withdrawal. This viewpoint article provides an overview of managing MOH in Australian clinical practice, with a focus on the importance of patient education and the role of preventive treatment in supporting patients as they withdraw from acute migraine medication(s).
format Online
Article
Text
id pubmed-10255228
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102552282023-06-10 Assessing and managing medication overuse headache in Australian clinical practice Wijeratne, Tissa Jenkins, Bronwyn Stark, Richard J Sun-Edelstein, Christina BMJ Neurol Open Viewpoint More than 3 million Australians are estimated to have migraine disorders, and over a quarter of a million Australians are estimated to have medication overuse headache (MOH). The personal, societal and economic burden of MOH is high. MOH impacts an individual’s ability to work or study, care for family or themselves, culminating in poor quality of life. Accurate and timely diagnosis and treatment of MOH are imperative. Withdrawal failures and relapse rates are high in MOH. Treatment of MOH is aimed at ceasing medication overuse and reducing monthly migraine days with the aim of achieving a pattern of well-controlled episodic migraine. Current treatment approaches in routine practice include withdrawal with preventive treatment, withdrawal with optional preventive treatment in the subsequent weeks and preventive treatment without withdrawal. This viewpoint article provides an overview of managing MOH in Australian clinical practice, with a focus on the importance of patient education and the role of preventive treatment in supporting patients as they withdraw from acute migraine medication(s). BMJ Publishing Group 2023-05-31 /pmc/articles/PMC10255228/ /pubmed/37304309 http://dx.doi.org/10.1136/bmjno-2023-000418 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Viewpoint
Wijeratne, Tissa
Jenkins, Bronwyn
Stark, Richard J
Sun-Edelstein, Christina
Assessing and managing medication overuse headache in Australian clinical practice
title Assessing and managing medication overuse headache in Australian clinical practice
title_full Assessing and managing medication overuse headache in Australian clinical practice
title_fullStr Assessing and managing medication overuse headache in Australian clinical practice
title_full_unstemmed Assessing and managing medication overuse headache in Australian clinical practice
title_short Assessing and managing medication overuse headache in Australian clinical practice
title_sort assessing and managing medication overuse headache in australian clinical practice
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255228/
https://www.ncbi.nlm.nih.gov/pubmed/37304309
http://dx.doi.org/10.1136/bmjno-2023-000418
work_keys_str_mv AT wijeratnetissa assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice
AT jenkinsbronwyn assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice
AT starkrichardj assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice
AT sunedelsteinchristina assessingandmanagingmedicationoveruseheadacheinaustralianclinicalpractice